高级检索
李春红, 杜宏金, 温小安, 孙宏斌. MDM2与MDM4抑制剂的研究进展[J]. 中国药科大学学报, 2015, 46(1): 1-15. DOI: 10.11665/j.issn.1000-5048.20150101
引用本文: 李春红, 杜宏金, 温小安, 孙宏斌. MDM2与MDM4抑制剂的研究进展[J]. 中国药科大学学报, 2015, 46(1): 1-15. DOI: 10.11665/j.issn.1000-5048.20150101
shu
LI Chunhong, DU Hongjin, WEN Xiao′an, SUN Hongbin. Advances in inhibitors of MDM2 and MDM4[J]. Journal of China Pharmaceutical University, 2015, 46(1): 1-15. DOI: 10.11665/j.issn.1000-5048.20150101
Citation: LI Chunhong, DU Hongjin, WEN Xiao′an, SUN Hongbin. Advances in inhibitors of MDM2 and MDM4[J]. Journal of China Pharmaceutical University, 2015, 46(1): 1-15. DOI: 10.11665/j.issn.1000-5048.20150101
shu

MDM2与MDM4抑制剂的研究进展

Advances in inhibitors of MDM2 and MDM4

    摘要
  • 摘要: p53在DNA修复、细胞周期阻滞、细胞凋亡、衰老、自噬及代谢等的调控中发挥着重要作用。MDM2和MDM4是p53的关键负调控因子，其抑制剂已成为抗肿瘤药物研究的热点。目前，7个MDM2抑制剂(RG7112，MI-77301，RG7388，AMG232，CGM097，MK-8242及DS-3032b)和1个MDM2/MDM4双重抑制剂(ALRN-6924)已进入临床研究阶段。本文重点从分子发现过程、药理活性、临床研究进展等方面对已进入临床研究的MDM2抑制剂进行综述，此外，还重点介绍MDM2/MDM4双重抑制剂的研究进展。

     

    Abstract: The protein p53 plays an important role in the regulation of DNA repair, cell cycle arrest, apoptosis, senescence, autophagy and metabolism. MDM2 and MDM4 are the key negative regulatory proteins of p53. Inhibition of MDM2 and MDM4 has become a research hotspot in cancer therapy. Currently, seven MDM2 inhibitors(RG7112, MI-77301, RG7388, AMG232, CGM097, MK-8242, DS-3032b)and one MDM2/MDM4 dual inhibitor(ALRN-6924)have entered clinical trials. This paper highlights small molecule discovery, pharmacological activities and clinical research advances of MDM2 inhibitors in clinical trials, in addition, this review introduces research advances of MDM2/MDM4 dual inhibitors.

     

    • HTML全文
    • 参考文献(84)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回

访问量：